Literature DB >> 21732777

Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values.

Nikita Makretsov1, C Blake Gilks, Reza Alaghehbandan, John Garratt, Louise Quenneville, Joel Mercer, Dragana Palavdzic, Emina E Torlakovic.   

Abstract

CONTEXT: External quality assurance and proficiency testing programs for breast cancer predictive biomarkers are based largely on traditional ad hoc design; at present there is no universal consensus on definition of a standard reference value for samples used in external quality assurance programs.
OBJECTIVE: To explore reference values for estrogen receptor and progesterone receptor immunohistochemistry in order to develop an evidence-based analytic platform for external quality assurance.
DESIGN: There were 31 participating laboratories, 4 of which were previously designated as "expert" laboratories. Each participant tested a tissue microarray slide with 44 breast carcinomas for estrogen receptor and progesterone receptor and submitted it to the Canadian Immunohistochemistry Quality Control Program for analysis. Nuclear staining in 1% or more of the tumor cells was a positive score. Five methods for determining reference values were compared.
RESULTS: All reference values showed 100% agreement for estrogen receptor and progesterone receptor scores, when indeterminate results were excluded. Individual laboratory performance (agreement rates, test sensitivity, test specificity, positive predictive value, negative predictive value, and κ value) was very similar for all reference values. Identification of suboptimal performance by all methods was identical for 30 of 31 laboratories. Estrogen receptor assessment of 1 laboratory was discordant: agreement was less than 90% for 3 of 5 reference values and greater than 90% with the use of 2 other reference values.
CONCLUSIONS: Various reference values provide equivalent laboratory rating. In addition to descriptive feedback, our approach allows calculation of technical test sensitivity and specificity, positive and negative predictive values, agreement rates, and κ values to guide corrective actions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732777     DOI: 10.5858/2010-0380-OAR1.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Modeling Canadian Quality Control Test Program for Steroid Hormone Receptors in Breast Cancer: Diagnostic Accuracy Study.

Authors:  Teresa Pérez; Nikita Makrestsov; John Garatt; Emina Torlakovic; C Blake Gilks; Susan Mallett
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016 Nov/Dec

Review 2.  Improving accuracy of breast cancer biomarker testing in India.

Authors:  Tanuja Shet
Journal:  Indian J Med Res       Date:  2017-10       Impact factor: 2.375

3.  Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).

Authors:  Carol C Cheung; Penny Barnes; Gilbert Bigras; Scott Boerner; Jagdish Butany; Fiorella Calabrese; Christian Couture; Jean Deschenes; Hala El-Zimaity; Gabor Fischer; Pierre O Fiset; John Garratt; Laurette Geldenhuys; C Blake Gilks; Marius Ilie; Diana Ionescu; Hyun J Lim; Lisa Manning; Adnan Mansoor; Robert Riddell; Catherine Ross; Sinchita Roy-Chowdhuri; Alan Spatz; Paul E Swanson; Victor A Tron; Ming-Sound Tsao; Hangjun Wang; Zhaolin Xu; Emina E Torlakovic
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019 Nov/Dec

4.  Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.

Authors:  Lidija Stevanovic; Matthias Choschzick; Linda Moskovszky; Zsuzsanna Varga
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-18       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.